ClinicalTrials.gg
TerminatedNCT00767481Updated Jul 19, 2012

1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT

A Phase 3 interventional study of Travoprost/Brinzolamide and Cosopt in Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Terminated at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-19.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Why this study was terminated
Project Cancelled

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.

Enrollment
38th of 39
6 · median 89
Started
2008
with 6 others
Phase 3
12 of 42
none open now
Registered
20th of 42
by date
Lead sponsor
27 of 42
Alcon Research

Among the 42 studies testing travoprost in Glaucoma, this one is the 38th largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2008, is one of 12 in phase 3, and was the 20th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing travoprost in Glaucoma as a file.
02

Study summary

Parallel, Multi-Center, Double-masked, Active controlled, three arm study comparing the IOP lowering efficacy and safety over 12 months of morning or evening instillations of Travoprost/Brinzolamide vs. Cosopt dosed in the morning and evening in patients with open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension

Keywords

  • glaucoma
  • Patients with open-angle glaucoma or ocular hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • IOP at screening visit \<18mmHg in at least one eye Mean IOP in same eye (at both eligibility 1 \&2 visits)

    • 24 and ≤ 36 mmHg at 9:00
    • 21 and ≤ 36 mmHg at 11:00 and 16:00

Exclusion criteria

Exclusion Criteria:

  • Severe central visual field loss Angle Shaffer grade \< 2 C/D ratio > 0.8 (horizontal or vertical measurement)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Travoprost/Brinzolamide PM, Vehicle AM

    Travoprost/Brinzolamide PM, Vehicle AM

    Drug: Travoprost/Brinzolamide

  • Experimental
    Travoprost/Brinzolamide AM, Vehicle PM

    Travoprost/Brinzolamide AM, Vehicle PM

    Drug: Travoprost/Brinzolamide

  • Active comparator
    Cosopt

    Cosopt BID

    Drug: Cosopt

Interventions

06

What researchers measure

Primary outcomes

  1. Mean IOP

    Time frame: 9:00,11:00, and 1600 time points at month 12

Secondary outcomes

  1. Percent change in IOP, IOP change from baseline, patients with IOP <18mmHg. BSCVA, Ocular signs, Dilated fundus, perimetry, pachymetry, cardiovascular parameters(pulse, BP and AEs at W2, W3, M6, M9 and M12.

    Time frame: All on therapy time points not included in primary efficacy

07

Study locations

1 site
  • Mexico City, 6700, Mexico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2008
First posted
Oct 7, 2008
Start
Oct 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Last update
Jul 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00767481
Lead sponsor
Alcon Research
Collaborators
PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Oct 7, 2008
Start date
Oct 2008
Primary completion
Feb 2009
Completion
Feb 2009
Last update
Jul 19, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Travoprost · Brinzolamide

Start the discussion